These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 18423147

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW.
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [Abstract] [Full Text] [Related]

  • 25. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ.
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.
    Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL.
    Hepatology; 1998 Aug; 28(2):555-61. PubMed ID: 9696024
    [Abstract] [Full Text] [Related]

  • 28. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J, Wu GC, Zhang ZT, Wu P, Zhang D, Sun MC, Gao DC, Wang Y, Jia JD, Wang BE.
    Zhonghua Wai Ke Za Zhi; 2005 Aug 01; 43(15):976-9. PubMed ID: 16194352
    [Abstract] [Full Text] [Related]

  • 31. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW.
    Clin Transplant; 2006 Aug 01; 20(3):369-73. PubMed ID: 16824156
    [Abstract] [Full Text] [Related]

  • 32. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D.
    Gastroenterology; 2008 Jun 01; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [Abstract] [Full Text] [Related]

  • 33. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.
    Torresi J.
    J Clin Virol; 2002 Aug 01; 25(2):97-106. PubMed ID: 12367644
    [Abstract] [Full Text] [Related]

  • 34. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA.
    Lancet; 1997 Jan 04; 349(9044):20-2. PubMed ID: 8988118
    [Abstract] [Full Text] [Related]

  • 35. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H.
    Liver Int; 2005 Dec 04; 25(6):1169-74. PubMed ID: 16343068
    [Abstract] [Full Text] [Related]

  • 36. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.
    Oon CJ, Chen WN, Lim N, Koh S, Lim GK, Leong AL, Tan GS.
    Antiviral Res; 1999 Apr 04; 41(3):113-8. PubMed ID: 10320044
    [Abstract] [Full Text] [Related]

  • 37. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study.
    Freshwater DA, Dudley T, Cane P, Mutimer DJ.
    Transplantation; 2008 Apr 27; 85(8):1105-11. PubMed ID: 18431229
    [Abstract] [Full Text] [Related]

  • 38. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection.
    Kumar GT, Kazim SN, Kumar M, Hissar S, Chauhan R, Basir SF, Sarin SK.
    J Gastroenterol Hepatol; 2009 Apr 27; 24(4):588-98. PubMed ID: 19207682
    [Abstract] [Full Text] [Related]

  • 39. Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis.
    Santantonio T, Gunther S, Sterneck M, Rendina M, Messner M, Launois B, Francavilla A, Pastore G, Will H.
    Hepatogastroenterology; 1999 Apr 27; 46(27):1848-54. PubMed ID: 10430358
    [Abstract] [Full Text] [Related]

  • 40. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
    Ołdakowska-Jedynak U, Paczek L, Foroncewicz B, Mucha K, Nyckowski P, Zieniewicz K, Ziarkiewicz-Wróblewska B, Ziółkowski J, Pilecki T, Patkowski W, Górnicka B, Paczkowska A, Krawczyk M.
    Ann Transplant; 2007 Apr 27; 12(3):28-32. PubMed ID: 18290567
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.